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Abstract 
Eukaryotic translation elongation factor 1 epsilon 1, 
alias EEF1E1, is a protein-coding gene that plays a 
role in the elongation step of translation. In 
particular, it is an auxiliary component of the 
macromolecular aminoacyl-tRNA synthase complex 
(MARS).  
Its expression is found frequently altered in human 
cancer cells and it is considered a putative tumor 
suppressor gene.  
This review collects the data on DNA/RNA, the 
protein encoded and the diseases where EEF1E1 is 
involved. 
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Identity 
Other names: P18, AIMP3, ARS-interacting 
multifunctional protein 3, Multisynthase Complex 
Auxiliary Component P18, Elongation Factor P18 
HGNC (Hugo): EEF1E1 
Location: 6p24.3 
Figure. 1. EEF1E1 gene and splicing variants/isoforms.  The figure shows the locus on chromosome 6 of the EEF1E1 gene 
(reworked from https://www.ncbi.nlm.nih.gov/gene; http://grch37.ensembl.org; www.genecards.org)










EEF1E1 (eukaryotic translation elongation factor 1 
epsilon 1) was identified for the first time by Mao 
and colleagues in 1998 (Mao et al, 1998). EEF1E1 is 
a protein-coding gene that starts at 8,079,395 nt and 
ends at 8,102,595 nt from pter. It has a length of 
23,201 bp, counts 5 exons, and the current reference 
sequence is NC_000006.12.  
It is proximal to BLOC1S5 (biogenesis of lysosomal 
organelles complex 1 subunit 5, alias MUTED) 
gene. Read-through transcription exists between 
BLOC1S5 gene and EEF1E1 gene with forming the 
read-through transcript EEF1E1-BLOC1S5 (alias 
EEF1E1-MUTED) that is a candidate for nonsense-
mediated mRNA decay (NMD) and it is unlikely to 
produce a protein product (He et al, 2018).  
Near to the genomic sequence of EEF1E1 there is a 
strong promoter transcriptional element that is 
located at +1.0 kb. Enhancer transcriptional elements 
are located at +22.0 Kb and at +18.1 Kb respectively. 
Transcription 
Alternative splicing for EEF1E1 brings to multiple 
transcript variants. In addition, a read-through 
transcription is known between EEF1E1 and the 
neighboring downstream MUTED (muted homolog) 
gene.  
Two main alternative splicing transcript variants for 
EEF1E1 were detected although several others were 
reported.   
In addition, it was speculated the presence of six 
protein isoforms, but only two are properly 
described, i.e. the isoform 1 of 174 residues and the 
isoform 2 that counts 139 residues.  
The main characteristics of the alternative splicing 
transcript variants are reported in Table.1.  
The transcript variant 1 mRNA has reference 
sequence NM_004280.5 and it is 1047 bp long. The 
5'UTR counts 27 nt, the CDS is extended from 28 to 
552 nt, while the 3'UTR covers the last 495 nt.  
The transcript variant 2 mRNA has reference 
sequence NM_001135650.2 and it is 562 bp long. 
The 5'UTR counts 27 nt, the CDS is extended from 
28 to 447 nt, while the 3'UTR covers the last 115 nt.  
Pseudogene 
According to Entrez Gene, the analysis of the human 
genome revealed the presence of an EEF1E1-related 
pseudogene on chromosome 2. This pseudogene was 
appointed as eukaryotic translation elongation factor 
1 epsilon 1 pseudogene 1, alias EEF1E1P1 and it is 
classified as a processed pseudogene 
(http://www.ensembl.org/index.html). Its gene ID is 
100130388, its reference is NC_000002.12, and its 
location is 2q13. EEF1E1P1 starts at 111,887,890 nt 
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Table.1 Alterative splicing variants and isoforms of EEF1E1.  (reworked from http://grch37.ensembl.org; 
https://www.ncbi.nlm.nih.gov; https://web.expasy.org/protparam/; https://www.uniprot.org). ncRNA = non-coding RNA;  nonsense 
md =  nonsense mediated decay;  (?) = undetermined;  MW  = molecular weight;  pI = theoretical pI. 
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Figure.2 eEF1E1 protein.  Graphical representation of eEF1E1 protein isoforms with the evidence of the main verified post-
translational modifications (reworked from http://grch37.ensembl.org; https://www.ncbi.nlm.nih.gov; 
http://bioinf.umbc.edu/dmdm/gene_prot_page.php). 
 
It virtually encodes a non-coding transcript of 430 bp 
named EEF1E1P1-201 (Ensembl Ref: 
ENST00000446998.2). The real presence of this 
transcript and its possible role in the cell are totally 
unknown.  
If EEF1E1P1 has any regulatory role in the 
expression of the respective gene as described for 
others (Hirotsune et al., 2003), is only speculation in 
the absence of experimental evidence. Currently, 
there is no evidence about the involvement of this 
pseudogene in human cancers or in other diseases. 
Protein 
Description 
The eukaryotic translation elongation factor 1 
epsilon 1 (alias eEF1E1, p18, AIMP3) is the smallest 
component of the Multiaminoacyl-tRNA Synthetase 
complex (alias MARS). The exact position of 
EEF1E1 in the MARS complex is still unknown. 
However, it seems to be localized on the surface of 
the MARS complex and it seems to interact with the 
eEF1H complex (Deineko V.V., 2008).  
EEF1E1 is a small globular protein with a length of 
174 amino acids and a molecular weight of 19,8 kDa.  
eEF1E1 shows strong sequence similarity with 
eukaryotic translation elongation factor 1 beta 2 ( 
EEF1B2) and eukaryotic translation elongation 
factor 1 gamma ( EEF1G) (Quevillon and Mirande, 
1996) and with the N-terminal sequence of valyl-
tRNA synthetase (Deineko V.V., 2008).  
eEF1E1 shows many domains in both isoforms: the 
amino half terminal is unique for both isoforms and 
shows an N-terminal-like domain not well  
characterized followed by a linker domain, while the 
major differences between the two isoforms are in 
the carboxyl half terminal. In fact, in the carboxyl 
half terminal of isoform 1 there are reported two 
domain overlapping, i.e. a Glutathione S-transferase 
C-terminal-like domain (GST_C_AIMP3), folded in 
alpha-helical, and a more general and not well 
characterized C-terminal domain.  
In isoform 2, there is a unique region called C-
terminal domain of the Glutathione S-transferase 
family (GST_C_family). The fold of this domain is 
alpha-helical (see figure.2).  
EEF1E1 interacts with other members of the MARS 
complex and one interactional model was proposed 
(Mirande, 2017) although its exact interactions need 
to be still clarified.  
 Post-translational modifications.  Some post-
translational modifications are observed, such as 
phosphorylation and acetylation 
(https://www.ncbi.nlm.nih.gov). 
Expression 
eEF1E1 is expressed widely in human tissues and 
normal cells (https://www.genecards.org; 
https://www.proteinatlas.org/ENSG00000124802-
EEF1E1/tissue) while its expression is altered in 
many cancer types. Frequently it is downregulated in 
various cancer tissues (Park et al, 2005).  
Cells that show overexpression of eEF1E1 show an 
acceleration of senescence and also defects in 
nuclear morphology (Oh et al, 2010). 
Localisation 
EEF1E1 is located mostly in the cytoplasm but it was 
also found in the nucleus. 
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Figure 3. Cellular localization of eEF1E1(p18). In the figure is reported the cellular localization of eEF1E1 obtaining by 
immunofluorescent staining (antibody HPA027901). In particular, eEF1E1 shows to be localized both in cytosol and nucleoplasm 




It is well known that in eukaryotic cells the various 
components of translation machinery are properly 
organized into two main multienzyme structures: 
eEF1H (macromolecular eukaryotic translation 
elongation factor-1 complex), formed by the 
translation elongation factors (EEF1B2, EEF1D, 
EEF1G) and VARS (valyl-tRNA synthetase), and 
MARS (Multiaminoacyl-tRNA Synthetase complex 
or multi-tRNA synthetase complex, alias MSC), 
formed by nine aminoacyl-tRNA synthetases 
(AARSs) specific for amino acids Glu, Pro (EPRS1 
(glutaminylprolyl-tRNA synthetase)), Ile (IARS1), 
Leu (LARS1), Met (MARS1, methionyl-
tRNAsynthetase), Gln (QARS1), Lys (KARS1), Arg 
(RARS1), and Asp (DARS1) and other auxiliary 
non-synthetase protein components, called also 
aminoacyl-tRNA synthetase (ARS)-interacting 
multifunctional proteins (AIMPs), i.e AIMP1 (p43), 
AIMP2 (p38) and eEF1E1 (AIMP3, alias p18)( Cho 
et al, 2015; Shalak et al, 2007; Quevillon and 
Mirande, 1996).  
It is well known that in eukaryotic cells the various 
components of translation machinery Therefore, the 
main canonical function of eEF1E1 is to play a role 
as an auxiliary component of the macromolecular 
aminoacyl-tRNA synthetases complex in the 
elongation step of translation, in particular, it 
interacts with several aminoacyl-tRNA synthetases 
(Tao et al, 2017) and it could contribute to the 
anchorage of MARS complex to EF1H complex 
(Quevillon and Mirande, 1996).  
Other functions (non-canonical roles): in addition to 
what has already been said, it seems to play a role in 
embryonic development of the mammalian face 
and other structures (Fowles et al, 2003).  
eEF1E1 has the ability to translocate into the nucleus 
in response to DNA damage where it has a role in 
the DNA damage response  in association with 
serine/threonine kinases ATM / ATR and TP53. In 
fact, it was found a positive relationship between 
expression levels of eEF1E1 and TP53, i.e. high 
expression levels of eEF1E1 are correlated with 
elevated TP53 levels, while eEF1E1 depletion leads 
to the block of TP53 induction (Park et al, 2005). The 
eEF1E1 loss-of-function phenotype leads to various 
kinds of abnormalities: in particular, one allele 
inactivation increases the susceptibility to 
spontaneous tumors while the inactivation of both 
EEF1E1 alleles caused embryonic lethality (Park et 
al, 2005). The importance of eEF1E1 in 
embryogenesis is previously reported (Fowles et al, 
2003) while in the context of the tumors, eEF1E1 
could be a haploinsufficient tumor suppressor (Park 
et al, 2005) that can accelerate cellular senescence 
(Kang et al, 2012).  
eEF1E1 in involved in the  degradation of mature 
Lamin A  ( LMNA) which is a major component of 
the nuclear envelope matrix (Tao et al, 2017). 
Homology 
eEF1E1 is highly conserved and its homology 
between the species is reported in Table.2 
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Circos plot for fusion events involving eEF1E1. The picture summarizes all fusion events concerning eEF1E1 and its fusion 
partners (from https://fusionhub.persistent.co.in/search_genewise.html). 
 







Human H.sapiens EEF1E1 100 100 
Chimpanzee P.troglodytes EEF1E1 99.2 100 
Macaco M.mulatta EEF1E1 97.5 99.4 
Wolf C.lupus EEF1E1 92.5 96.0 
Cattle B.taurus EEF1E1 89.8 96.5 
Mouse  M.musculus Eef1e1 86.6 88.5 
Rat R.norvegicus Eef1e1 83.7 87.9 
Chicken G.gallus EEF1E1 75.9 77.6 
Xenopus 
tropicalis 
X.tropicalis Eef1e1 67.6 69.6 
Zebrafish  D.rerio Eef1e1 63.0 63.7 
Table.2 EEF1E1 homology (reworked from 
ps://www.ncbi.nlm.nih.gov/homologene) 
Mutations 
A great number of mutations in the genomic 
sequence and in the amino acid sequence for 
EEF1E1 were discovered in cancer cells that are 
obviously genetically more unstable respect normal 
ones. However, depletion of EEF1E1 causes itself 
genomic instability in cells (Kim et al, 2018) and 
makes the cells susceptible to transformation by 
single oncogenes (Park et al, 2006).  
The genomic alterations observed include also the 
formation of novel fusion genes. However, there are 
no sufficient experimental data yet to understand the 
repercussions on cellular behavior and so the 
implications in cancer of these alterations. 
Implicated in 
Top note 
A different expression level of EEF1E1 was 
observed in many cancer types compared to 
noncancerous control tissue. It is considered as a 
putative tumor suppressor, in particular for its 
downregulation in gastric and colorectal cancers 
(Kim et al, 2011). In fact, high EEF1E1 expression 
seems to be related to better survival in these two 
tumor types (Hassan et al, 2018).  
However, Hassan et colleagues reported that 
EEF1E1 is overexpressed in many other cancer types 
such as breast, lung, gastric, prostate, colorectal and 
liver tumors and this fact could predict poor survival 
(breast, lung, liver)(Hassan et al, 2018).  
Interesting is the role of inorganic arsenic (iAs) in 
the epigenetic alteration of DNA methylation in 
arsenic-induced diseases such as cancer of the 
bladder, kidney, lung, liver, and prostate. It was 
revealed that EEF1E1 is one of many genes silenced 
and involved in iAs related-hypermethylation in an 
arsenic-methylated tumor suppressorome (Smeester 
et al, 2011).  
In addition, eEF1E1 is involved in some genomic 
translocations with the creation of numerous fusion 
genes (Table.3). 
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Table.3 EEF1E1 rearrangements: translocations and fusion genes  (reworked from: http://www.tumorfusions.org; 
https://mitelmandatabase.isb-cgc.org/; http://quiver.archerdx.com; 
http://atlasgeneticsoncology.org//Bands/6p24.html#REFERENCES; [ (?) ] unknown;   [ 1 ] Hu et al, 2018; [ 2 ] Yoshihara    et al, 
2015; [ 3 ] Gao et al 2018; [ - ] no reference 
 
Ankylosing spondylitis 
It is found that the expression levels of EEF1E1 are 
significantly upregulated in whole blood of 
ankylosing spondylitis (AS) patients respect control 
group and these findings could be attributed to 
genetic mutations on EEF1E1 gene. This may have 
an important significance in the pathogenesis of AS 
because eEF1E1 may be involved in AS related-
inflammation by upregulating TP53 and pro-
inflammatory cytokines. This may suggest the use of 
EEF1E1 as an underlying genetic biomarker for the 
diagnosis of AS but other research are needed to 
determine the exact role of eEF1E1 overexpression 
in AS (Fan et al, 2019) 
Autism spectrum disorders 
EEF1E1 appears in research on developmental delay 
and autism spectrum disorders focused on deletions 
in chromosome 6p22.3-p24.3 (Celestino-Soper et al, 
2012). However, is still not clear its role in these 
diseases. 
Bladder cancers 
In general, eEF1E1 is found to be down-regulated in 
bladder cancers. eEF1E1 is expressed at moderate 
and high levels in all normal urothelium tissues 
while only a part of bladder cancers shows this 
expression's pattern. The loss of eEF1E1 expression 
is more evident in late-stage (≥ T2) bladder tumours 
and can be associated with survival in muscle-
invasive bladder cancers (MIBC) patients following 
radiotherapy (Gurung et al, 2015). 
Brain and central nervous system 
(CNS) cancers 
EEF1E1 is upregulated in astrocytoma and 
oligodendroglioma while for glioblastoma and 
glioma no significant difference in expression levels 
was observed. High levels of EEF1E1 could be 
predicted better survival outcomes (Hassan et al, 
2018). In addition, one genomic alteration was 
observed both in astrocytoma and glioblastoma, i.e. 
the fusion gene t(6;6)(p24;p24) RREB1 /EEF1E1 
(Gao et al, 2018; Yoshihara et al, 2015). There are 
no data about the respective chimeric transcript or 
protein and so this genomic alteration is still poorly 
understood. 
Breast cancer 
Currently, for EEF1E1 there is no significant 
difference in expression, between breast cancer and 
normal breast tissues (Hassan et al, 2018; Guglielmi 
et al, 2013). The prognostic significance for EEF1E1 
is that a higher expression level has a significant 
correlation with relapse-free survival (RFS) and 
distant metastasis-free survival (DMFS) but not with 
either overall survival (OS) or post-progression 
survival (PPS) while high expression levels of 
EEF1E1 are strongly associated with poor RFS in the 
luminal A and B subtypes (Hassan et al, 2018).  
Other authors reported that EEF1E1 is down-
regulated in breast cancer and linked to the genomic 
instability of these cells (Iofrida et al, 2012). In 
addition, some genomic alteration was observed in 
breast adenocarcinoma such as the translocation 
Name 5' end 3' end Loc1 Loc2 Description Type Disease Organ Code Ref.  
CDYL/EEF1E1 CDYL EEF1E1 6p25 6p24.3 t(6;6)(p25;p24) Translocation Malignant melanoma Skin SKCM 1 
EEF1E1/AEBP2 EEF1E1 AEBP2 6p24.3 12p12.3 t(6;12)(p24;p12) Translocation - - - - 
EEF1E1-BLOC1S5 EEF1E1 BLOC1S5 6p24.3 6p24.3 
Readthrough 
transcription 
Fusion gene - - - - 
EEF1E1/CD2AP EEF1E1 CD2AP 6p24.3 6p12.3 t(6;6)(p24;p12) Translocation - - - - 
EEF1E1/DSC2 EEF1E1 DSC2 6p24.3 18q12.1 t(6;18)(p24;q12) Translocation - - - - 
EEF1E1/EYS EEF1E1 EYS 6p24.3 6q12 t(6;6)(p24;q12) Translocation Adenocarcinoma Breast BRCA 2 
EEF1E1/KRTDAP EEF1E1 KRTDAP 6p24.3 19q13.12 t(6;19)(p24;q13) Translocation - - - - 
EEF1E1/NSMCE4A EEF1E1 NSMCE4A 6p24.3 10q26.13 t(6;10)(p24;q26) Translocation - - - - 
EEF1E1/RAB23 EEF1E1 RAB23 6p24.3 6p12.1 t(6;12)(p24;p12) Translocation - - - - 
EEF1E1/RREB1 EEF1E1 RREB1 6p24.3 6p24.3 t(6;6)(p24;p24) Fusion gene - - - - 
INPP4A/EEF1E1 INPP4A EEF1E1 2q11 6p24.3 t(2;6)(q11;p24) Translocation 
Mesenchymal tumor, 
NOS 
- - 1 
PSMG4/EEF1E1 PSMG4 EEF1E1 6p25 6p24.3 t(6;6)(p25;p24) Translocation Adenocarcinoma Breast BRCA 1 







TG/EEF1E1 TG EEF1E1 8q24.22 6p24.3 t(6;8)(p24;q24) Translocation - - - - 
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t(6;6)(p24;q12) EEF1E1/ EYS and t(6;6)(p25;p24) 
PSMG4 /EEF1E1 (Hu et al., 2018). There are no data 
about the respective chimeric transcripts or proteins 
and so these genomic alterations are still poorly 
understood. 
Colorectal cancer 
EEF1E1 was found to be upregulated in rectal 
mucinous adenocarcinoma subtype and, in general in 
colorectal cancers compared to normal tissues. A 
reduction of its expression level correlates with a 
worst prognosis and poor survival (Hassan et al, 
2018). Other studies found that normal colon mucosa 
expressed EEF1E1 in nearly all of the cases while 
EEF1E1 expression is significantly decreased in the 
majority of colorectal cancer (CRC) cases. This 
suggests that the downregulation of EEF1E1 may be 
related to inactivation of its tumour suppressor 
function and so might play a role in the development 
of CRC (Chen et al, 2018; Kim et al, 2011) 
Gastric cancer 
In gastric cancers is found an upregulation of 
EEF1E1 transcript and this predicts a better overall 
survival (OS) and first progression (FP)(Hassan et al, 
2018). Other studies revealed that normal gastric 
mucosa expressed EEF1E1 in nearly all of the cases 
while EEF1E1 expression is significantly decreased 
in the majority of gastric cancer (GC) cases. This 
suggests that the downregulation of EEF1E1 may be 
related to the inactivation of its tumour suppressor 
function and so might play a role in the development 
of GC (Kim et al, 2011). 
Head and neck squamous cell 
carcinoma (HNSC) 
EEF1E1 is found to be overexpressed in head and 
neck cancers (Hassan et al, 2018). Wiest and 
colleagues (Wiest et al, 2002) have found an 
interesting feature in the HPV16 infection in some 
samples of head and neck cancer in relation to 
EEF1E1. In detail, the integration site of E6/E7 
region of HPV16 falls on chromosome 6 in the 
proximity of some human genes included EEF1E1. 
This could contribute to explain the oncogene 
property of HPV16 or one of the oncogenesis 
mechanisms of head and neck cancer. However, it is 
still unclear if the viral integration can affect the 
regulation of expression of EEF1E1. 
Kidney cancer 
EEF1E1 was found to be downregulated in 
chromophobe renal cell carcinoma and in kidney 
clear cell carcinoma (Hassan et al, 2018). 
Liver cancer 
It was documented that eEF1E1 is down-regulated in 
hepatocellular carcinoma (HCC)(Yu et al, 2017; Du 
et al, 2012). In particular, there is a high relation 
between the expression levels of highly up-regulated 
in liver cancer (HULC) long non-coding RNA and 
eEF1E1 in HCC. In fact, if HULC is over-expressed 
the expression levels of eEF1E1 fall down and on the 
contrary if expression levels of HULC decrease, 
eEF1E1 is expressed normally. EEF1E1 gene is in 
close proximity to HULC gene and with high 
probability the second can mediate the expression 
levels of the first (Yu et al, 2017). Other authors 
reported that EEF1E1 expression levels are higher in 
liver cancer and that this could predict worse 
survival although they did not tell precisely the 
cancer type (Hassan et al, 2018). 
Lung cancer 
EEF1E1 expression levels were reported to be high 
in small cell lung carcinoma, in squamous cell lung 
carcinoma subtypes, and in large cell lung 
carcinoma. These high expression levels seem to be 
correlated with poor overall survival (OS) and first 
progression (FP) in lung cancers (Hassan et al, 
2018). In addition, were reported some somatic 
mutations for EEF1E1 gene in lung cancer cell lines 
(Kim et al, 2011). 
Lymphoma and other blood cancers 
EEF1E1 is found to be overexpressed in Burkitt's 
lymphoma and in diffuse large B-Cell lymphoma. 
On the contrary, it is found to be downregulated in 
marginal zone B-Cell lymphoma (Hassan et al, 
2018), acute promyelocytic leukemia and chronic 
myelogenous leukemia (Gurung et al, 2015). In 
chronic myelogenous leukemia was observed some 
somatic mutations for EEF1E1 (Kim et al, 2011). In 
addition, EEF1E1 shows an increased expression in 
pyothorax-associated lymphoma (PAL), a 
lymphoma developing in long-standing 
inflammation (Nishiu et al, 2004). 
Ovarian cancer 
It is detected that EEF1E1 is frequently upregulated 
in ovarian serous adenocarcinoma (Hassan et al, 
2018). 
Pancreatic cancer 
EEF1E1 expression levels were found to be 
significantly downregulated in pancreatic cancers 
(Hassan et al, 2008). 
Prostate cancer 
EEF1E1 is significantly overexpressed in prostate 
cancer. Currently, there is not sufficient data about  
 
 
the prognostic significance of the upregulation of 
EEF1E1 in prostate cancer (Hassan et al, 2018). 
To be noted 
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HIV-1 interactions: It is reported that HIV-1 MA 
protein interacts with EEF1E1 in human HEK293 
and Jurkat cell lines (Jäger et al, 2011) and that 
EEF1E1 is subject to cleavage by the HIV-1 protease 
(Impens et al, 2012). 
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